Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balfour

Showing results (331-340 of 1,706) with videos related to

Pageof 171
Sort By:
Pharmacoeconomics|April 8, 1993
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infectionsJ A Balfour, D Faulds
Drugs|March 1, 1996
MeloxicamS Noble, J A Balfour
Pharmacoeconomics|July 6, 1996
Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infectionsJ A Balfour, P Benfield
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 25, 2002
Advances in neuroscience and pharmacology of nicotine. 3rd SRNT Europe Conference, Paris, France, 19-22 September 2001David Balfour, Jacques Le Houezec
Drugs|February 1, 1992
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycosesJ A Balfour, D Faulds
Journal of Gastroenterology|September 5, 2019
Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseasesYoshiyuki Mishima, Ryan Balfour Sartor
The Journal of Chemical Physics|October 10, 2009
Visible bands of divanadiumWalter J Balfour, Runhua Li
Advances in Experimental Medicine and Biology|January 1, 1973
Contact sensitivity in the pigD E McFarlin, B Balfour
Annals of Internal Medicine|January 1, 1987
Cytomegalovirus and acute cholecystitisA Erice, H H Balfour
Digestive Diseases and Sciences|February 2, 2020
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel DiseasesAkihiko Oka, R Balfour Sartor
Pageof 171

Showing results (331-340 of 1,706) with videos related to

Sort By:
Pageof 171
Pharmacoeconomics|April 8, 1993
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infectionsJ A Balfour, D Faulds
Drugs|March 1, 1996
MeloxicamS Noble, J A Balfour
Pharmacoeconomics|July 6, 1996
Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infectionsJ A Balfour, P Benfield
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 25, 2002
Advances in neuroscience and pharmacology of nicotine. 3rd SRNT Europe Conference, Paris, France, 19-22 September 2001David Balfour, Jacques Le Houezec
Drugs|February 1, 1992
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycosesJ A Balfour, D Faulds
Journal of Gastroenterology|September 5, 2019
Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseasesYoshiyuki Mishima, Ryan Balfour Sartor
The Journal of Chemical Physics|October 10, 2009
Visible bands of divanadiumWalter J Balfour, Runhua Li
Advances in Experimental Medicine and Biology|January 1, 1973
Contact sensitivity in the pigD E McFarlin, B Balfour
Annals of Internal Medicine|January 1, 1987
Cytomegalovirus and acute cholecystitisA Erice, H H Balfour
Digestive Diseases and Sciences|February 2, 2020
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel DiseasesAkihiko Oka, R Balfour Sartor
Pageof 171